We discuss our experience using the new Cera TM and Ceraflex TM (Lifetech, Nashan, Shenzhen, China) devices in closing PDAs, an ASD and PFOs.
INTRODUCTION

Patent ductus arteriosus (PDA) and atrial septal defects (ASD)
are two of the most common congenital cardiac lesions occurring in 0.5/1 000 and 0.67 -2.1/1 000 of live births respectively, with a higher incidence of PDAs in premature babies. (1, 2) Historically the only treatment available for these lesions was surgery. The first percutaneous closure of a PDA by Porstman, et al. (2) in 1967 and ASD closure by King and Mills in 1976, (3) led to the development of various new techniques and devices over the past four decades. (4) (5) (6) The advantages of percutaneous closure of these lesions are well described and are now the standard of care.
The Ceraflex TM devices come loaded, are attached by a nitinol wire ( Figure 1a ) and need to be flushed before implantation. 
RESULTS
Twenty devices were implanted: PDA (n=16), ASD (n=1) and PFO (n=3). Clinical and implantation data can be viewed in Table 1 . In the PDA group the median age was 1y 10mo
(4mo -10y 4mo) and median weight was 10.5kg (4.9kg -70kg).
Male to female ratio was 1:3 (4 males, 12 females). No significant gradients were observed in the left pulmonary artery and aorta post implantation. Complete closure was obtained in all patients.
The patient with an ASD was a 27-year-old female weighing 56kg. The median age and weight for PFO closure was 50y 9mo
(38y -70y) and 82.5kg (80kg -113kg) respectively. Peri-procedural trans-esophageal echocardiogram confirmed no interference or obstruction of intra-cardiac structures.
Complications
No major complications were observed. Two PDA devices embolised to the aorta, one immediately after release and the other after 12 hours. These devices could be snared and repositioned with no further complications (see discussion). All patients were discharged within 24 hours, except the 2 patients with device embolisations.
Follow-up
Follow-up periods ranged from 1mo -25mo. (mean 13.0 ± 7.6mo). All patients were asymptomatic with complete defect closure. There was no aortic or pulmonary artery obstruction that was noted on follow-up in the PDA group. In the ASD/ PFO group, the ECGs were normal, the devices were in a good position and there was no valvular regurgitation or pericardial effusion. A mechanism is easy to use and effective. The PDA device cost is comparable to other available devices whilst the ASD and PFO devices are considerably less in our setting. An advantage of the CeraFlex TM device is that the device is in its final position before release due to the nitinol wire mechanism (Figure 3 ).
DISCUSSION
ASD and PFO closure was successful in the selected patients.
The devices could be recaptured if the position was unacceptable before release. Care was taken to confirm distance from AV valves, SVC, IVC and no impingement of the aorta before release. If a deficient aortic rim was of concern, the device was slightly oversized to prevent aortic impingement.
Our experience of the 2 PDA devices that embolised merits further discussion. Both of these patients were small (4.8kg and 6kg) and were closed using the smaller device (0406). In one patient the device embolised immediately and in the smaller infant the embolisation was noted 12 hours post implantation.
The mechanism of embolisation may be due to a number of factors. Incorrect device selection may play a role. We do, however, take care not to cross the PDA before initial angiogram to ensure accurate measurements. We also use the right anterior oblique (RAO) 30 o view to measure the PDA in more than one plane. We then select a device as recommended by the manufacturer. If concern exists about sizing, we advance the delivery sheath through the PDA and repeat the aortogram for final measurements and sizing. In both cases the smaller device was used. One possible explanation is that the smaller device may take longer to conform to its original expanded size at body temperature. The authors speculate that the most likely cause may be that the nitinol wire loop becomes wedged in the mesh of the device at the anchor point. The delivery cable acts as a slingshot when one tries to withdraw the wire during release ( Figure 2 ). Tension remains on the system with pulling in the direction of the pulmonary artery. As a result, the device jumps in the direction of the aorta on final release (slingshot mechanism) and may dislodge. This may be more likely to occur in smaller devices.
Following these 2 incidents, we now protect the aorta by placing a pigtail catheter in the ductal ampulla before final release. We also pull the sheath back into the IVC to reduce the tension on the delivery cable and wait for 5 -10min before ASD AND PDA CLOSURE 
Limitations
This is a retrospective review with a small number of patients and relatively short follow-up.
CONCLUSION
The Cera TM and CeraFlex TM devices are an effective alternative to commercially available devices. Certain precautionary measures are advised in small children where smaller devices are used.
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A B FIGURE 3: Illustrates the PFO device.
A & B: Illustrates the PFO device in its final position after deployment, before nitinol wire release.
